Intraoral/intranasal niclosamide/HPBCD formulation for treatment of COVID-19
A recently published patent of Union Therapeutics, Denmark (US11045434) (granted extremely rapidly by USPTO within 8 months from filing date)
Category: Uncategorized
CAVACURMIN®: Study Reveals Increased Metabolic Bioavailability of Tetrahydrocurcumin
A study recently published in the Journal of Functional Foods shows that ingestion of the curcumin-cyclodextrin complex CAVACURMIN® leads to an
NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who
Happy 70th Birthday, Lajos!
CycloLab celebrates birthday of L. Szente (70), former CEO Lajos Szente has been contributing to the development of the global
Changes in the management of CycloLab
Cyclolab, a company with unparalleled expertise in the manufacturing, design and formulation of cyclodextrins, announced the appointment of Tamas Sohajda
Use of sulfobutylether beta cyclodextrin for preparing ceramics
A very few patent applications may trace back prior art disclosure to the Neolithic Age (from 10000 – 4500 BC)
500th post in Cyclodextrin News blog
1986, the year of the first issue of Cyclodextrin News was abundant in notable events and new threats to be
FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
New cyclodextrin with orphan drug designation: SBECD
ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug